Akebia Therapeutics
AKBA
87 hedge funds and large institutions have $73.5M invested in Akebia Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
169% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $494K
27% more capital invested
Capital invested by funds: $58M → $73.5M (+$15.5M)
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
14% more funds holding
Funds holding: 76 → 87 (+11)
2.42% more ownership
Funds ownership: 27% → 29.42% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.66M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.44M |
| 3 |
Morgan Stanley
New York
|
+$954K |
| 4 |
BlackRock
New York
|
+$682K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$748K |
| 2 |
Millennium Management
New York
|
-$462K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$314K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$101K |
| 5 |
JP Morgan Chase
New York
|
-$96.5K |
AKBA Hedge Fund Activity: Q4 2023 in Review
87 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2023, worth a combined $73.5M — up 27% from $58M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AKBA positions and 4 closed out — a net gain of 11 holders — while 23 added to existing stakes and 20 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.66M. The largest seller was Victory Capital Management, cutting an estimated $748K.
- 87 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2023, up from 76 in Q3 2023.
- Funds reported $73.5M of Akebia Therapeutics stock for Q4 2023, up 27% quarter-over-quarter.
- 15 funds opened new Akebia Therapeutics positions in Q4 2023 and 4 closed out, a net change of +11 holders.
- The largest Akebia Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $1.66M added.
- The largest Akebia Therapeutics seller in Q4 2023 was Victory Capital Management, an estimated $748K sold.
Based on aggregated 13F filings for Q4 2023.